Traduction de «further » (Français → Néerlandais) :

Further interdisciplinary discussion on this matter is also necessary" [traduction libre: L'offre en vente directe de tests de dépistage préconceptionnel des porteurs jette le doute sur l'offre de soins préconceptionnels et sur l'offre systématique de dépistage des porteurs à une population de couples envisageant une grossesse.
Further interdisciplinary discussion on this matter is also necessary" .

A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K.
A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K. # # # # #

This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.

The medical risk of any stroke or death in the forthcoming five years in symptomatic persons of the NASCET/ECST trials with a stenosis of 50% (according to the NASCET method) was 21%. 14 That risk was further increased by male sex (23%), old age ( 75 y, 31%), time since last event (< 2 weeks, 32%) and diabetes.
The medical risk of any stroke or death in the forthcoming five years in symptomatic persons of the NASCET/ECST trials with a stenosis of 50% (according to the NASCET method) was 21%.[14] That risk was further increased by male sex (23%), old age ( 75 y, 31%), time since last event (< 2 weeks, 32%) and diabetes.

First and most important, for symptomatic stenosis patients, the number needed to treat to benefit within two years is between 3 to 19, depending on degree of stenosis and age. 15 For asymptomatic stenosis, as the Kaplan Mayer-curve suggests, at least five years of follow-up are needed to recoup the lost life years by increased morbidity and mortality (see further).
First and most important, for symptomatic stenosis patients, the number needed to treat to benefit within two years is between 3 to 19, depending on degree of stenosis and age.15 For asymptomatic stenosis, as the Kaplan Mayer-curve suggests, at least five years of follow-up are needed to recoup the lost life years by increased morbidity and mortality (see further).